Open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
This is a open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients. Pharmacokinetic (PK) interaction between ABP-671 and Allopurinol will be evaluated in participants who are on stable Allopurinol therapy.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• Adults 18-75 years with clinical diagnosis of gout.
• Stable Allopurinol therapy QD for ≥14 days prior to Day 1.
• Cohort N: Normal renal function.
• Cohort R: Moderate renal impairment.
Locations
United States
North Carolina
Wakefield Clinical Research
RECRUITING
Cary
Contact Information
Primary
MaoE Sun
mao.e.sun@atombp.com
13914017855
Time Frame
Start Date: 2026-01-23
Estimated Completion Date: 2026-08-31
Participants
Target number of participants: 20
Treatments
Experimental: ABP-671
Sponsors
Leads: Atom Therapeutics Co., Ltd